PDL BioPharma - Selling off Noden
PDL BioPharma recently announced an agreement to divest its Noden subsidiary to Stanley Capital for up to $48.25m in cash. $12m is due at deal...
96 Views
PDL BioPharma - Evofem shares distributed and Phexxi approved
PDL distributed its 26.7% Evofem stake to shareholders on 21 May 2020, just before the 22 May 2020 FDA approval for Evofem’s hormone-free...
117 Views
PDL BioPharma - Accelerating asset monetization
PDL BioPharma announced that the company is targeting either a complete sale or the monetization of its four key assets by the end of 2020, much...
533 Views
PDL BioPharma - Returning value to shareholders
PDL BioPharma has a portfolio of healthcare-related assets. These include the Assertio royalty stream, covering rights for extended release (XR)...
574 Views
PDL BioPharma - Company to seek to monetize assets
PDL BioPharma (PDL) has announced that following the completion of a strategic review process it has decided to cease additional strategic...
1.6k Views
No more insights